Tysabri

According to biogen idec, outside of clinical trials, approximately 5000 patients with ms have received tysabri through their primary physician; however, because tysabri was approved only recently, these patients have only received at most a few doses of tysabri. Your Plan May Have Coverage Limits Your Plan may have certain coverage limits. For example, prescription drugs used for cosmetic purposes may not be covered, or a medication might be limited to a certain amount such as the number of pills or total dosage ; within a specific time period. If you submit a prescription for a drug that has coverage limits, your pharmacist will tell you that approval is needed before the prescription can be filled. The pharmacist will give you or your doctor a toll-free number to call. If you use Medco By Mail, your doctor will be contacted directly. When a coverage limit is triggered, more information is needed to determine whether your use of the medication meets your Plan's coverage conditions. We will notify you and your doctor of the decision in writing. If coverage is approved, the letter will indicate the amount of time for which coverage is valid. If coverage is denied, an explanation will be provided, along with instructions on how to submit an appeal. If tests show carotid stenosis greater than 70%, a carotid endarterectomy may be performed. During this surgical procedure, the carotid artery is opened and the plaque removed. Nursing care focuses on careful neurological assessment for signs of deterioration related to ischemia. The incision is monitored for hematoma development and bleeding. Development of a hematoma can compromise the patient's airway. Bleeding at the suture line, particularly of bright red blood, may indicate failure of the sutures. This emergency situation requires prompt response to prevent massive blood loss. Balloon angioplasty for carotid stenosis is being investigated as a potential treatment in large facilities. Rates of motor recovery vary across management categories: patients suffering minor stroke recover rapidly with few or no residual deficits whereas severely impaired individuals demonstrate more limited and prolonged recovery. The initial grade of paresis, measured on initial hospital admission, is an important predictor of motor recovery. Motor function often improves after the first few days. In the case of complete paralysis on admission, complete motor recovery occurs in less than 15 percent of patients.102 Recovery has been demonstrated in a wide variety of patients, including those with extensive central nervous system CNS ; damage and advanced age.103112 Patients with small lacunar strokes demonstrate improved motor recovery over patients with large, hemispheric lesions.113 In an extensive review of the literature, Hendricks et al102 found no significant difference in potential for motor recovery between type of stroke hemorrhage vs infarction ; and location brainstem vs hemispheric infarction ; . Functional mobility skills are impaired following stroke and vary considerably from individual to individual. During the acute stroke phase, 70 to 80 percent of patients demonstrate mobility problems in ambulation while 6 months to 1 year later the figures are reversed, with only 20 percent of patients needing help to walk independently. Basic ADL skills such as feeding, bathing, dressing, and toileting are also compromised during acute stroke, with 67 to 88 percent of patients demonstrating partial or complete dependence. Independence in ADL also improves with time with only 31 percent of survivors requiring partial or total assistance a year later.114, 115 The ability to perform functional tasks is influenced by a number of factors. Motor and perceptual impairments have the greatest impact on functional performance, but other limiting factors include sensory loss, disorientation, communication disorders, and decreased cardiorespiratory endurance. Enablement factors include high motivation, stable supportive family, financial resources, and intensive training with repetitive practice!

Country or group of countries Western Europe Standard MOX fuel1 N. of pins irradiated 265 000 Burn-up reached MWd t 135 000 Experimental fuel Maximum burn-up MWd t 200 0002 Main reactors3 Phnix, PFR, KNK-II FFTF Joyo BOR-60 BN-350 BN-600 Type of fuel3 Solid and annular pellets Leading pins Solid pellets Vibro-pac fuel Solid and annular pellets Solid and annular pellets. E-MAP115 ensconsin ; does not modulate microtubule dynamics in vivo 4249 cells abundantly expressing GFP-MAP chimeras Table 3 ; . Finally, it was striking that endogenous E-MAP-115 ensconsin ; , detected by immunofluorescence, showed identical distribution in TC-7 cells Fig. 5k-o ; , or in MCF-7 cells data not shown ; . These data show that E-MAP-115 ensconsin ; does not dissociate from spindle MTs in either cell line we examined, in contrast to behavior reported in HeLa cells Masson and Kreis, 1995 ; . subtracted 2GFP-EMTB images from X-rhodamine images; the result is shown for the two time points in Fig. 6C and D. We saw no indication of MTs or MT ends lacking bound 2GFP-EMTB, although we did note lateral movement of some MTs Fig. 6, subjacent MTs noted by arrowheads ; . To examine this point further, we analyzed the ends of MTs in 2GFP-EMTB-TC-7-L cells by a technique independent of lateral movements. We generated life-history plots of the ends of red and green MTs, from the sequence excerpted in Fig. 6. In the example shown in Fig. 6E, tracking at intervals separated by 1.5 seconds revealed that at no time did the length change of the MT end, determined from GFP-EMTB and Xrhodamine-tubulin images, differ by more than one micron, a value within our experimental error for MT tracking. These results suggest that the rate that MAP binds to the MT lattice is at least as rapid as the rate of tubulin association to growing ends during steady-state polymer assembly in these cells. To address the dynamics of MAP association with MTs during de novo polymerization, rather than under steady-state in vivo conditions, we depolymerized all cellular MTs with nocodazole, microinjected cells with X-rhodamine tubulin, and performed a nocodazole washout during dual-wavelength timelapse fluorescence imaging. In 2GFP-EMTB-TC-7-L cells in which MTs were depolymerized by nocodazole 0: 0. 0 minutes; Fig. 7a ; 2GFP-EMTB fluorescence appeared diffuse, as did X-rhodamine tubulin fluorescence in the same and valcyte. There can be no assurance that tysabri will be returned to the market, the timing of such return, if ever, or that even if subsequently marketed and sold, the product will result in our receiving any significant royalties from the sales of tysabri. The major risk when taking tysabri is a disease called pml, which stands for progressive multifocal leukoencephalopathy and valdecoxib. 7.2.5.2 Urine Bioassay. Urine bioassay is a versatile technique for measuring a wide range of systemically excreted radionuclides. Collection of urine is relatively straightforward, convenient, and easy to manage. Several example protocols for collection of urine to be used for dosimetry purposes are shown in Table 7.1. Following collection, the sample must be analyzed by a radioanalytical procedure appropriate for the radionuclide s ; of interest.
Login register home about archives local events resources jobs blogroll advertise e-mail - podcasts - rss related posts biogen's busy week, alnylam's big announcement, targanta's and momenta's growing executive ranks, & more life sciences news biogen idec's tysabri approved for crohn's bidding for biogen idec could begin in early november, report says biogen idec-icahn story likely far from over; history says the activist investor will act again carl icahn ups biogen idec stake-now owns 3 percent; also buys shares in genzyme biotech , drugs , fda biogen bouncing back from tysabri warning news rebecca zacks 2 28 08 shares of biogen idec nasdaq: biib ; are climbing back up today after taking a dip yesterday on news that tysabri, which biogen markets in partnership with ireland’ s elan, may cause liver damage and valerian.
The imposition of a new rule has always caused a furor among the alwa students. Sangram Kadam and Zishaan present their contrasting views. hostels. The quickly changing policy makes For more rules and regulations the reasoning behind the rules seem very reedom on college campuses, in my opinshaky. What seems to be a little harsher is the new phenomenon of time restrictions ion, is a relative term. It is often seen that of entry and exit from the campus. One students in colleges with restrictive poligets a feeling that we are heading towards cies, may never bicker, because that is what the idea of a hostel, where everybody wakes they are used to encountering all their life. up to a bell at 7: 30 and lights go out at On the other hand many a student from the more liberal 11 pm. colleges will veIt is imperative for hemently protest the authorities to the imposition expect some sense of any new rules, of maturity and responsibility from the students. It is a telling however small it may be. So, where does tale, if the country's brightest twenty year one draw the line? What exactly does one olds cannot be trusted without a charter of imply by "being free" and by "freedom"? How much "freedom" is the right amount trivial do's and don't's. Another problem that tends to be ignored of "freedom"? is the freedom in exercising one's academic While all of us love freedom, one must bear choices. Although the situation varies from in mind that rules are in place for a good program to program; our academic poli- reason. I remember my cousins asking me cies are quite rigid when it comes to cours- if my routine involved waking up at the es, projects, and the like. Even extra and stroke of 6 in the morning, eating breakco-curricular activities which were a great fast at 8: 00 long table, attending avenue of fun and frolic for students, along classes at 9: 00 and sleeping at 10: 00 pm! with being a learning ground for life skills; For quite a few of us who have never experienced hostel life before joining the are now bogged down by restrictions. While rules like the ban on drinking and IITs, I sure this was the dominant picsmoking, strict imposition of speed lim- ture. It was hard for me to explain and difits for vehicles mind you not just student ficult for them to digest that there were vehicles ; , penaliziation of academic dis- absolutely no restrictions on time and honesty seriously, etc. seem logical; what movement in and out of the hostel camseems unjustified is completely phasing pus. And they were surprised when I told out vehicles, absurd time restrictions on them that my hostel warden wouldn't even freedom of movement of students, provid- know if I left the city! ing little or almost no option in choice of So much, so good. But how does one justify one's "freedom"? Civil society, runs electives are there any at all? ; , etc. Harvard president Derek Bok's warnings on the premise, that following the rules is are to be seriously thought about, "What beneficial to all; and that the cost we pay in universities can and must resist are delib- terms of our freedom benefits in the form erate, overt attempts to impose orthodoxy of greater security and convenience. One and suppress dissent. In recent years, the must learn to look at authorities not as threat of orthodoxy has come primarily demon-figures, trading in the freedom and from within rather than outside the uni- happiness of the student community for versity." At the age of about twenty years, their own ends. The least that is expected when responsibilities are given, maturity is responsible behavior. And in the absence will be shown. One cannot be achieved of such responsible behavior, is it wrong for the authorities to implement and without the other. Sangram Kadam is a fifth year dual degree enforce newer or modified rules? student of the Dept. of Elec. Engg. and can Sometimes the imposition of one rule is necessary to prevent the be contacted at sangram ee.iitb.ac.in. Fig. 2. Time Course of I3C Regulation of ER and ER Protein Expression in MCF7 and T47D Breast Cancer Cells MCF7 and T47D breast cancer cells were treated with either DMSO or 200 M I3C for varying durations as indicated. Isolated total cell extracts were electrophoretically fractionated, and immunoblot analysis for ER and ER was carried out as described in Materials and Methods. CDK2 protein levels have been shown to remain unaltered with I3C treatment and were used as a protein loading control and valganciclovir.

There was a 50% reduction p 0.001 ; in MS related hospitalizations in both trials. Using a non-specific quality of life QOL ; scale, there was a statistically significant improvement in physical function for both trials but no significant improvement in the mental components. There was also improvement with a QOL scale that was specific for MS, especially in fatigue and pain. Patients in the AFFIRM trial completed follow-up this week. Two-year disability data will be presented at Annual meeting of the American Academy of Neurology, April 9-16, 2005. Over 80% of the patients in SENTINEL have been followed for over 2 years. 2-year data should be available in H1 05. 4. LAUNCH OF TYSABRI ON TRACK Biogen IDEC started to ship Tysabri this week. Dosing of patients should begin next week. The wholesaler acquisition costs is , 808 per 300 mg vial. The approved dosing of Tysabri is 300 mg per month. Patients were treated for 116 weeks in both the AFFIRM and SENTINEL pivotal trials. During the meeting, management discussed additional details regarding its commercial strategy. a ; Intravenous IV ; access. Biogen IDEC has identified 1, 300 points of IV access which cover about 50% of currently treated patients. They would be able to receive infusions in the physician office or at a nearby hospital. Home infusion would account for 10-11% of patients, initially. About 40% of patients will be treated at free standing clinics and less accessible physician offices and hospitals. Long term, home infusion will likely gain popularity due to the convenience for patients, less concern about side effects after the first few courses, and lower cost to the payers. Reimbursement for each infusion is about , 000 in hospitals and possibly 50% less at home. b ; Reimbursement. Biogen IDEC has had over 700 meetings with payers. Management indicated that to date, none of the a payers have refused to cover Tysabri based on the 1 year data. However, there may be delays in setting up the paper work and in educating physician staff to file claims using the manual J code. c ; Distribution. Biogen IDEC will offer multiple distribution models tailored to different points of administration. For patients receiving treatment in the physician office, physicians may purchase product from the wholesaler or use a specialty pharmacy. The former requires the physician to assume the inventory and reimbursement risks and ties up cash flow but the margin is higher. About 10% of payers, eg Kaiser, require the physician to use a specialty pharmacy. 5. PHASE III DATA ON RITUXAN IN RHEUMATOID ARTHRITIS AND BG 12 IN PSORIASIS EXPECTED IN NEXT 6 MONTHS a ; Rituxan in RA. Genentech presented top line data from a Phase IIb trial of Rituxan in DMARD refractory rheumatoid arthritis RA ; in November 2004. Data from a Phase III trial in TNF refractory patients is expected in H1 05. Favorable data may be sufficient to support an FDA application. The market potential for TNF failures is 0-500MM. b ; BG-12. Biogen IDEC licensed BG-12, a second-generation oral fumurate from Fumapharm. Results from a European Phase III trial are expected by yearend. The trial randomized 175 patients to either 240 mg of BG-12 three times a day or placebo. The primary endpoint is PASI score at 16 weeks. In a Phase II trial of BG-12, 64% of patients receiving the 720 mg dose achieved a PASI 50 and 75 responses at week 12 versus 42% of placebo patients. Gastrointestinal side effects were found in 50% of patients, which is less than that with the first generation fumurate. Biogen IDEC expects to use the EU Phase III results for filing in Germany by mid-2005. Depending on the outcome of the EU trial, Biogen IDEC may initiate a Phase III trial in the US. 6. PIPELINE UPADTE and tysabri.

Negative Adjusted EBITDA related to Tysabri increased to 3.9 million for the full-year 2005 from 9.5 million for the full-year 2004. This reflects the costs of the initial launch of Tysabri in the fourth quarter of 2004, the voluntary suspension of Tysabri in February 2005 and the subsequent safety evaluation, together with the costs of keeping the commercial infrastructure in place in anticipation of the potential re-marketing of Tysabri in 2006 and vancomycin.

HILADELPHIA chromosome Ph' ; -positive chronic myelogenous leukemia CML ; is a pleuripotent stem cell disease characterized by two distinct clinical phases: an initial chronic phase lasting for 2 to 4 years, followed by a fatal blastic crisis.', * Previous therapy using single-agent chemotherapy, as well as combination chemotherapy, failed to achieve a sustained suppression of Ph'.3.4The advent of allogeneic bone marrow transplant and interferon therapy has resulted in durable complete clinical and cytogenetic remi~sion.', ~ However, disease recurrence and progression remains a major problem. Relapse from subclinical minimal residual disease is the most likely mechanism. The polymerase chain reaction PCR ; is a molecular technique that permits the detection of neoplastic cells with a chromosomal translocation at a level less than one in lO0, OOO.' This assay provides a unique opportunity to explore the biology of minimal residual disease in patients who are thought to be in complete remission. Ph' in CML involves a reciprocal translocation of the BCR gene and c-ab1 Depending on where the chromosomal breakpoint at the bcr region occurs, the fused BCRlabl gene transcribes into one of two types of chimeric BCRlabl transcripts: L-6 bcr exon I1 and c-ab1 exon "2" linkage or b2 a2 linkage ; or K-28 bcr exon 111 and c-ab1 exon "2" linkage o r b31a2 linkage ; ." Taking advantage of these unique molecular characteristics, we and others have.
Of-age group studied.40 Little data, however, have been published chronicling the levels or temporal changes in elderly controls as a result of the normal aging processes.41 Although the normal rate of change in parenchymal volume has been reported to be approximately 0.25% per year during the life span of most healthy humans, 42 WBNAA is hypothesized to remain relatively stable even in later years. Because it is normalized to the brain volume equation 2 ; , it should be relatively insensitive to this normal atrophy, reflecting only the health of neurons in the remaining tissue. WBNAA in MS MS the most common autoimmune, demyelinating, neurodegenerative disease in young adults. It strikes nearly 2.5 million people worldwide at a cost of approximately billion for treatment and management in the United States alone : nationalmssociety ; . It is unknown etiology, though 2 of every 3 new patients are women in their late 20s. Its prevalence among men or of all people of African or Asian descent is less than half that of women.43 Most 85%90% ; new patients with MS follow a relapsing remitting RR ; course characterized by relapses of variable severity followed by remissions of varying duration.43 Nearly 20% will remain clinically stable for at least 2 decades, a phenotype referred to as benign MS.44 Within 25 years, however, most untreated patients with RRMS will evolve into a secondary-progressive SP ; phase of a steady increase in chronic disability. Some 10%15% of new patients with MS follow a primary-progressive PP ; course, characterized by late onset and steady increase in disability.45 Although still without cure, 6 drugs are currently approved by the US Food and Drug Administration as disease-modifying agents that alter the natural history of MS. These include the following: intramuscular beta-interferon-la Avonex ; , subcutaneous beta-interferon-1a Rebif ; , subcutaneous betainterferon-1b Betaseron ; , glatiramer acetate Copaxone ; , and natalizumab Tysabri ; , a laboratory-produced monoclonal antibody given by intravenous infusion. For SPMS, the most convincing data favors mitoxantrone Novantrone ; as most likely to retard progression and delay disability.46-48 Extensive 1H-MR spectroscopy studies to characterize the metabolic profiles of MS lesions as well as the normal-appearing white and gray matter NAGM ; revealed loss of NAA in all tissue types, confirming the diffuse nature of the pathologic processes underlying the disease.49 This was confirmed by the first WBNAA study, which demonstrated age-dependent deficits in patients compared with matched controls in both RR-50 and PPMS.51 This dependence is probably due to the similar age of onset, transforming patients' "age" to "disease-duration." Although lesions and atrophy, shown in Fig 5, the hallmarks of MS, represent end points of its complex pathologic processes, lesions do not identify these processes. Comparing WBNAA levels with atrophy reflected by the fraction of parenchymal brain volume ; as functions of disease duration in a cohort of 42 patients with RRMS has found the former to decrease nearly 3.5 times faster than the latter.52 This suggests that neuronal cell injury precedes atrophy and that that degenerating axons may leave behind their empty myelin sheaths and vaniqa.